津药达仁堂集团股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 6 月 9 日 目 录 现场会议召开时间：2025 年 6 月 9 日下午 2:00 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 | 1 | 公司转让所持有中美天津史克制药有限公司 12%股权暨签订《股权转 | 3 | | --- | --- | --- | | 序号 | 议案 让协议》的议案 | 页码 | 2025 年第一次临时股东大会 文件目录 2 2025 年第一次临时股东大会 议案一 议案 1：关于公司转让所持有中美天津史克制药有限公司 12%股 权暨签订《股权转让协议》的议案 公司于 2025 年 4 月 14 日召开 2025 年第二次董事会，会议审议 通过了"公司转让所持有中美天津史克制药有限公司 12%股权暨签订 《股权转让协议》的议案"。现将该议案提交公司 2025 年第一次临时 股东大会审议，议案具体情况如下： 一、交易概述 津药达仁堂集团股份有限公司（以下简称"公司"）所属参股公 司中美天津史克制药有限公司（以下简称"天津史克"）是一家中外 合资有 ...

Group 1 - The market experienced a slight adjustment last week, with the brand index closing at 1657.60 points, while several component stocks rose against the trend, including Xinlitai, Tigermed, and Stone Technology [1][2] - Xinlitai led the gains with an increase of 14.96%, followed by Tigermed at 12.48%, and Stone Technology at 11.47%. Other notable gainers included Three Squirrels and Supor, which rose by 7.69% and 6.07% respectively [2] - Since the beginning of 2025, Maimai Biological has seen a significant increase of 51.27%, with Shanghai Jahwa and Xinlitai also showing strong performance with gains of 47.96% and 47.71% respectively [3] Group 2 - Looking ahead, the market is expected to gradually shift towards a more positive trend as investors remain sensitive to favorable factors, with ongoing accumulation of positive elements supporting economic expectations and fundamentals [4] - The current market structure indicates a potential for mid-term positive performance, driven by policy support, domestic technological breakthroughs, and a favorable external environment, which may enhance liquidity in the domestic capital market [4] - In the medium to long term, opportunities may arise in sectors such as domestic demand, technology, and overseas expansion, with a focus on defensive dividend sectors and aggressive technology sectors, including internet and robotics [5]

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]

Group 1 - The core viewpoint of the articles indicates that the market is expected to experience a steady upward trend supported by policy measures and liquidity easing, with a focus on technology growth and consumer recovery as the main driving forces [1][2] - The Central Political Bureau meeting emphasized timely interest rate cuts and reserve requirement ratio reductions, which are expected to release liquidity through structural tools, thereby solidifying the market bottom [1] - In Q1 2025, the net profit attributable to shareholders of A-shares turned positive year-on-year, with significant recovery in the profitability of small and medium-sized stocks, particularly in the TMT and consumer sectors [1] Group 2 - The CSI 500 Quality Growth Index consists of 100 listed companies selected for their high profitability, sustainable earnings, and strong cash flow, providing diverse investment options for investors [2] - As of April 30, 2025, the top ten weighted stocks in the CSI 500 Quality Growth Index accounted for 24.07% of the index, with notable companies including Chifeng Jilong Gold Mining and Ninebot [2][4] - The 500 Quality Growth ETF closely tracks the CSI 500 Quality Growth Index, offering investors a way to invest in these high-quality growth companies [2][4]

北京观韬（天津）律师事务所 关于津药达仁堂集团股份有限公司 一、本次股东会的召集和召开程序 北京 · 上海 · 西安 ·成都 · 大连 · 深圳 ·济南 · 厦门 · 香港 · 天津 · 广州· 杭州 Beijin·Shanghai·Xi'an·Chengdu·Dalia·Shenzhen·Jinan·Xiamen·Hong Kong·Tianjin·GuangZhou·HangZhou 1 本次股东会由公司董事会根据 2025 年 3 月 28 日召开的 2025 年第一次董事 会决议召集，公司董事会于 2025 年 3 月 28 日、2025 年 5 月 9 日在 SINGAPORE EXCHANGE LIMITED(新加坡证券交易所)网站(http://www.sgx.com)刊登了《津药 达仁堂集团股份有限公司关于召开 2024 年年度股东大会的通知》（以下简称"《会 议通知》"）及本次股东会的提示性公告；同时，公司董事会于 2025 年 3 月 31 日、2025 年 5 月 12 日在中国证监会指定的信息披露报刊《中国证券报》、《上 海证券报》及上海证券交易所网站（http://www.sse.c ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-017 号 津药达仁堂集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 15 日 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：公司 2024 年度董事长工作报告 审议结果：通过 表决情况： (二)股东大会召开的地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 544 | | --- | --- | | 其中：A 股股东人数 | 521 | | 境外上市外资股股东人数（S 股） | 23 | | 2、出席会议的股东所持有表决权的股份总数（股） | 334,593,319 | | 其中：A 股股东持有股份总数 | 331,010,576 | | 境外上市外资股股东持有股份总数（S ...

Core Viewpoint - The Chinese traditional medicine industry is experiencing collective anxiety due to insufficient effective demand, accelerated industry transformation, policy changes, and intense market competition [1] Industry Performance Overview - The performance of traditional Chinese medicine companies in 2024 and the first quarter of 2025 shows a diverging trend, with some companies achieving stable growth through brand advantages and product innovation, while others face revenue declines and profit pressures [1][3] - In 2024, Baiyunshan led the industry with a revenue of 749.93 billion yuan, but experienced a slight decline of 0.69% year-on-year, indicating growth challenges for traditional giants [3][6] - Yunnan Baiyao and China Resources Sanjiu followed with revenues of 400.33 billion yuan and 276.17 billion yuan, reflecting year-on-year growth rates of 2.36% and 11.63%, respectively [3][6] - In the first quarter of 2025, leading companies continued to show growth, while trailing companies remained under pressure [1][6] Profitability Insights - Yunnan Baiyao reported a net profit of 47.67 billion yuan in 2024, maintaining a growth rate of 15.63%, while Pizhou's net profit reached 29.96 billion yuan, aligning with its revenue growth [6] - Daren Tang emerged as a "profit dark horse" with a net profit increase of 128.68% year-on-year, while Dong'e Ejiao's net profit grew by 25.57% due to product price increases and channel optimization [6][1] R&D and Sales Expenses - In 2024, the highest R&D investment was from Tianshili, amounting to 1.039 billion yuan, representing 12.23% of its revenue [6][7] - Sales expenses were highest for China Resources Sanjiu at 72.20 billion yuan, followed by Baiyunshan at 56.20 billion yuan [7] - The overall R&D investment among the top 20 companies indicates a need for improvement, especially in innovative drug development and modern Chinese medicine technology applications [7] Market Challenges and Strategic Responses - The unique product strategy, once a cash cow for many companies, is now facing challenges due to adjustments in medical insurance directories and expanded centralized procurement [9][10] - Companies like Step Long Pharmaceutical have reported significant losses due to high sales expenses and declining core product revenues [1][6] - The industry is witnessing a trend where companies are either "slimming down" by divesting non-core assets or "bulking up" through mergers and acquisitions to strengthen their market position [14][15] Future Outlook - The ongoing centralized procurement and market dynamics necessitate that companies balance pricing and market share while building brand moats [12][14] - Companies with unique proprietary formulas, such as Pizhou and Yunnan Baiyao, are better positioned to withstand market fluctuations compared to those reliant on single products without strong patent protection [11][12]

证券代码：600329 证券简称：达仁堂 公告编号：2025-016 号 津药达仁堂集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 5 月 15 日 13 点 30 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-016 号 津药达仁堂集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 15 日 13 点 30 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 一、 召开会议的基本情况 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易 ...

目 录 现场会议召开时间：2025 年 5 月 15 日下午 1:30 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 津药达仁堂集团股份有限公司 2024 年度股东大会 会议资料 2025 年 5 月 15 日 2024 年度股东大会 文件目录 董事长工作报告 董事长 王磊 各位股东： 2024 年，达仁堂集团持续落实"一个中心、八大行动框架"工作主题，务 实推进品牌建设，市场营销，科技创新，精益生产等经营发展工作，持续提升品 牌力、产品力、服务力。 报告期内，在主业经营外，公司所持商业业务和联营企业股权资产有所调整。 公司以旗下全资子公司天津中新医药有限公司的全部股权作价，增资津药太平医 药有限公司，增资完成后，公司持有的商业业务资产以所持津药太平医药有限公 司 43.35%股权体现，为公司的联营公司，公司合并报表不再确认该业务资产收 入，仅按股权比例确认损益。2024 年公司年报确认商业业务的收入为 31.1 亿元， 同比下降 17.3%。 报告期内，医疗、医保、医药领域政策和市场不断发展，行业机遇与挑战并 存，国家统计局数据显示，全国规上医药制造业 ...